NXTC nextcure.com: Enterprise Value to EBITDA Ratio

Graphic logo of NextCure (NXTC)

NextCure, Inc. (NXTC) possesses significant market influence due to the exclusivity of the FIND platform, which enables the identification of hidden immune-suppressor proteins. Demand for such solutions remains independent of economic cycles or GDP. This chart of the share price is based on the value of 0.00. Stable, world-renowned management and partnerships with industry behemoths ensure high shareholder confidence.

NextCure Corp - NXTC Total Company Value to Operating Income Before Depreciation Ratio (period 11/23/2025 - 11/10/2026)

Summary analytical data breakdowns for nextcure.com (NXTC)

- stock price and consensus target price:
Stock Quotes NextCure Corp|NXTC - Average Forecast Price
- company stock capitalization data:
Market Valuation NextCure Corporation|NXTC - Value Adjusted for Debt and Cash
- business book valuation details:
Book Value per Share NextCure|NXTC - Book Valuation of Business|Market Value to Book Value Ratio nextcure.com|NXTC - Cumulative Company Assets
- debt and solvency information:
Debt to Equity NextCure, Inc.|NXTC - Long-Term Debt to Equity Ratio|Short-Term Debt to Equity Ratio NextCure|NXTC - Company Aggregate Debts|Debt to Book Capitalization Ratio NextCure Corporation|NXTC - Company Long-Term Indebtedness|Company Short-Term Debt NextCure|Quick Liquidity Indicator nextcure.com
- financial results and valuation multiples details:
NXTC - Annual Net Income|Future Profit NextCure, Inc.|NXTC - Market Price to Net Income Ratio|Forward P/E Multiple NextCure, Inc.|NXTC - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple NextCure Corporation|NXTC - Profit before interest, taxes and amortization|Earnings per share for the last twelve months NextCure|NXTC - Earnings per share for the trailing year|Quarterly EPS earnings growth nextcure.com|NXTC - Earnings growth in current year|Net earnings per share growth forecast for next year NextCure, Inc.
Fundamental company analysis:NXTC (NextCure Corp)
Original product of NextCure Inc

This indicator reflects the ratio of total enterprise value, including net debt, to earnings before interest, taxes, depreciation, and amortization, allowing for an assessment of the real value of assets relative to their yield. By analyzing the EV/EBITDA history of NextCure, Inc. (NXTC), an investor can see how resilience to macro cycles and the success of clinical trials impact the company's capitalization, determining the extent to which its market capital is overvalued or undervalued.

Competitor analysis for NextCure, Inc.

ImmunityBio Corp - Enterprise Value to EBITDA Ratio|Immunocore Corp (IMCR) - Company Value to EBITDA|JANX: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation RCUS (arcusbio.com)|ZYME: EV/EBITDA Multiple|TNGX - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Iovance|Enterprise Value to EBITDA Ratio Immatics Biotechnologies (IMTX)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Xencor, Inc. (XNCR)|Enterprise Value to EBITDA Ratio compasstherapeutics.com CMPX|Replimune - Enterprise Value to EBITDA Ratio|EV/EBITDA Multiple Lyell LYEL|IPHA - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|PYXS (Pyxis Oncology, Inc.) - Enterprise Value to Operating Income Before Depreciation|cgen.com (CGEN) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA iobiotech.com (IOBT)|Enterprise Value to EBITDA Ratio STRO|INKT - Enterprise Value to EBITDA Multiple|Enterprise Value to EBITDA Ratio HOWL (Werewolf Therapeutics)|Enterprise Value to Operating Income Before Depreciation Ratio IMMX|EV/EBITDA Multiple ALXO (ALX Oncology)|Business Value to Operating Income Before Depreciation CUE|PDS Biotechnology Corp - EV/EBITDA Multiple|Company Value to EBITDA Sonnet BioTherapeutics|MAIA Biotechnology Inc (MAIA) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Liminatus - Business Value to Operating Income Before Depreciation|LVTX (LAVA Therapeutics NV) - EV/EBITDA Multiple|EV/EBITDA Multiple Leap Tx|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Intensity Therapeutics (INTS)|SNSE: Company Value to Operating Income Before Depreciation Ratio|Synthetic Biologics - Enterprise Value to EBITDA Ratio|Gritstone bio Inc. (GRTS) - Company Value to EBITDA|KA - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|NEXI (neximmune.com) - Enterprise Value to Operating Income Before Depreciation|TSBX: EV/EBITDA Multiple|Company Value to EBITDA Vaccinex Inc. (VCNX)|Enterprise Value to EBITDA Ratio HARP